<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28533610</article-id><article-id pub-id-type="pmc">5430273</article-id><article-id pub-id-type="publisher-id">jpts-2016-864</article-id><article-id pub-id-type="doi">10.1589/jpts.29.685</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of transcutaneous electrical nerve stimulation on
chemotherapy-induced peripheral neuropathy symptoms (CIPN): a preliminary case-control
study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tonezzer</surname><given-names>Tania</given-names></name><degrees>PT</degrees><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caffaro</surname><given-names>Leonardo Affonso Massabki</given-names></name><degrees>PT</degrees><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Menon</surname><given-names>Katiuscia Rosette Scasni</given-names></name><degrees>PT</degrees><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brandini da Silva</surname><given-names>Fab&#x000ed;ola Cristina</given-names></name><degrees>PT</degrees><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moran de Brito</surname><given-names>Christina May</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sarri</surname><given-names>Almir Jos&#x000e9;</given-names></name><degrees>PT, PhD</degrees><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Casarotto</surname><given-names>Raquel Aparecida</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><aff id="aff1"><label>1)</label> Department of Rehabilitation Sciences in the School of
Medicine, Department of Physical Therapy, Speech and Occupational Therapy, University of
S&#x000e3;o Paulo, Brazil</aff><aff id="aff2"><label>2)</label> Department of Physiotherapy Course of University of S&#x000e3;o
Francisco, Brazil</aff><aff id="aff3"><label>3)</label> Barretos Cancer Hospital, Brazil</aff><aff id="aff4"><label>4)</label> Rehabilitation Department of the Cancer Institute at the
University of S&#x000e3;o Paulo School of Medicine, Brazil</aff><aff id="aff5"><label>5)</label> Department of Physiotherapy, Barretos Cancer Hospital,
Brazil</aff><aff id="aff6"><label>6)</label> Department of Physical Therapy, Speech and Occupational
Therapy, School of Medicine of the University of S&#x000e3;o Paulo, Brazil</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tania Tonezzer, Department of
Rehabilitation Sciences in the School of Medicine, Department of Physical Therapy, Speech
and Occupational Therapy, University of S&#x000e3;o Paulo: Rua Cipot&#x000e2;nea 51, Cidade Universit&#x000e1;ria,
S&#x000e3;o Paulo, SP, CEP 05360-160, Brazil. (E-mail: <email xlink:href="ttonezzer@usp.br">ttonezzer@usp.br</email>)</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>29</volume><issue>4</issue><fpage>685</fpage><lpage>692</lpage><history><date date-type="received"><day>21</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>2017&#x000a9;by the Society of Physical Therapy Science. Published by IPEC
Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0:
<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>&#x0ff09;. </license-p></license></permissions><abstract><p>[Purpose] The aim of this double-blind, randomized and placebo-controlled study is to
investigate the effects of Transcutaneous Electrical Nerve Stimulation for reducing the
side effects of Chemotherapy-induced Peripheral Neuropathy in cancer patients undergoing
chemotherapy with oxaloplatin or paclitaxel. [Subjects and Methods] Twenty-four patients
were randomly allocated into two groups: active or placebo stimulation. All patients were
assessed for pain, numbness/tingiling, frequency of symptoms, and quality of life. The
transcutaneous Electrical Nerve Stimulation device was applied daily with modulating
frequencies ranging between 7&#x02005;Hz and 65&#x02005;Hz in distal limb regions during three cycles of
chemotherapy (45 days). The other stimulation parameters were: pulse duration of 200 &#x003bc;sec,
intensity at the highest tolerable level, and increases in intensity when it diminished.
[Results] The data showed no difference between active or placebo groups in terms of pain,
numbness/tingling, frequency of symptoms or impact on daily life activities. [Conclusion]
These results suggest that Transcutaneous Electrical Nerve Stimulation applied in the
frequency variation mode was not proven to be effective to improve the symptoms of
Chemotherapy-induced Peripheral Neuropathy during chemotherapy cycles. There was no
worsening of symptoms in subsequent cycles of the onset of symptoms of the disease.</p></abstract><kwd-group><kwd>Transcutaneous electric nerve stimulation</kwd><kwd>Chemotherapy-induced peripheral neuropathy</kwd><kwd>Physical therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>The use of chemotherapy drugs is the basis for the systemic treatment of cancer<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. While these drugs kill tumor cells, they
can also cause adverse effects during their use, such as nausea, vomiting, diarrhea,
constipation, alopecia, fatigue, skin alterations, and neurotoxicity, among others.</p><p>Chemotherapy-induced peripheral neuropathy (CIPN) is a nuisance and a limiting side effect
for patients, since the symptoms of pain, dysesthesia, and paresthesia generated by
chemotherapy can mean a reduction in the functionality and quality of life for cancer
patients. Moreover, these side effects may compromise the treatment of the disease and lead
to reduced doses of drugs or treatment discontinuation<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>.</p><p>The current recommendations of the American Society of Clinical Oncology (ASCO)<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup> point out that there are not yet any
strongly recommended drugs available to prevent CIPN, given the lack of consistent and
high-quality research on the issue. Chu&#x02019;s<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>
review about the effects of antidepressant drugs and anticonvulsants for the control of CIPN
confirm ASCO&#x02019;s data. Therefore, the treatment of these disorders could ideally be done
without the use of drugs by applying non-pharmacological treatments, which would have the
advantage of not compromising the different body systems already burdened by
chemotherapy.</p><p>Transcutaneous Electrical Nerve Stimulation (TENS) has arisen as an alternative to drug
treatment for the control of peripheral neuropathies. The rationale for the use of TENS is
based on studies showing that electrical stimulation has shown a positive effect on rat&#x02019;s
nerve regeneration, revealing a higher number of myelinated fibers, axon density, and blood
vessels in the total nerve area compared to control groups<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>. When using Transcutaneous Electrical Stimulation in mice&#x02019;s
peripheral nerve injuries, the density, fiber diameter, and degree of myelination are also
similar to animals that have not suffered injuries<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>.</p><p>A case-control study evaluated the effect of TENS on peripheral neuropathic pain induced by
chemotherapy in patients with different types of cancer, pointing out beneficial effects in
reducing pain during TENS application without generating side effects<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. Silva<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>
used TENS in the treatment of intercostobrachial pain developed after breast cancer surgery
to show that, in addition to pain relief, TENS produced changes in somatotopic organization
in the parietal cortex after application, causing increased attention to painful processes.
This increased attention would cause an inhibition in the transmission of painful
stimuli.</p><p>Other symptoms of CIPN, such as paresthesia and decreased quality of life of these
patients, have not been evaluated in previous controlled studies. Therefore, this study aims
to evaluate the effects of TENS on symptoms of numbness and tingling and the frequency of
symptoms and its impact on the daily life activities of patients with CIPN.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>This two-arm clinical trial was randomized, placebo-controlled, and double-blind. It was
conducted in cancer patients who developed symptoms of CIPN after the first chemotherapy
cycle. The patients were recruited in Barretos Cancer Hospital, Institute of Cancer of the
State of S&#x000e3;o Paulo, and S&#x000e3;o Francisco University Hospital. This study was approved by the
Research Ethics Committee of the Faculty of Medicine, University of S&#x000e3;o Paulo, under
protocol n&#x000ba; 341/13. It was registered at ClinicalTrials.gov before the research began, under
registration number NTC 02107417. All participants were informed about the objectives of the
study and signed a consent form to participate in the study.</p><p>The study included patients between the ages of 18 and 70 who met the following inclusion
criteria: being subjected to chemotherapy treatment with drugs with a high to moderate
degree of neurotoxicity, experiencing neuropathic pain and/or peripheral sensory neuropathy
of grade I or grade II on the Common Terminology Criteria for Adverse Events (CTCAE) scale,
exhibiting symptoms of peripheral neuropathy after the first cycles of chemotherapy with at
least two points on the visual analog scale of paresthesia and/or pain, and having a present
performance status of ECOG &#x02264;2 (Karnofsky&#x02265;50%).</p><p>Exclusion criteria were: having sensitivity disorders before chemotherapy treatment, having
skin lesions on the site of application of the electrodes, exhibiting cognitive difficulties
or trouble understanding how to fill out questionnaires, or being cardiac pacemaker users or
diabetes mellitus patients.</p><p>The study sample consisted of 24 patients with diagnoses of breast and colorectal cancer
undergoing a chemotherapy treatment containing in its protocol the chemotherapeutic agents
paclitaxel or oxaliplatin. Patients were divided into 2 groups: active TENS (GAT) and
placebo TENS (GPT). Patients underwent TENS application for 45 days, daily. The flowchart of
the research is shown in <xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>The flow diagram of the research</p></caption><graphic xlink:href="jpts-29-685-g001"/></fig>.</p><p>The entry of patients in each experimental group was performed randomly by the site
www.random.org before the start of treatment. Patients were subjected to the following TENS
(Ibramed, Neurodyn Port&#x000e1;til) parameters: symmetrical biphasic waveform with modulating
frequencies ranging from 7&#x02005;Hz to 65&#x02005;Hz, a pulse width of 200&#x02005;&#x000b5;s at the highest tolerable
current intensity with an application time of 60 minutes. The stimulation was performed with
individual self-adhesive electrodes with an area of 5&#x02005;cm<sup>2</sup> in the region where the
patient had symptoms of neuropathy, typically, the ends of the upper limbs and/or lower
limbs. In the application of active TENS, the patient was instructed to increase the
stimulation intensity each time the intensity reduced during the 60 minutes of
application<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. In TENS placebo
application, patients received the same schedule of active TENS, but the equipment was
produced to apply the current for only 30 seconds and then the intensity began to decrease
during the next 15 seconds until reaching zero<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>.</p><p>The evaluations were performed by a blinded evaluator on the experimental groups.</p><p>We used the following instruments for data collection:</p><p>-Sociodemographic and clinical data form to characterize the sample profile with the
following data: gender, age, race, education, type of cancer, occupational status and
disease status. TNM Rating (T, refers to the size and extent of the main tumor; N refers to
the number of nearby lymph nodes that have cancer; M refers to metastasis), treatments
conducted (surgical, radiotherapy, hormonal, chemotherapy, other types of medication,
acupuncture) and affected segment by neuropathy (upper limb and/or lower limb) were also
used to create the profiles.</p><p>-Common Terminology Criteria for Adverse Events&#x02212;CTCAE version 4.02 of 20090. Items of the
questionnaire used to assess the symptoms of CIPN were paresthesia (grade I, II, and III),
peripheral sensory neuropathy (I, II, III, IV, and V), and dysesthesia (grade I, II, and
II).</p><p>-Visual analog scale for pain and paresthesia assessment (VAS).</p><p>-Performance Status scale ECOG (Eastern Cooperative Oncology Group) to assess the
functional capacity of oncologic patients, with the following scores and activity levels: 0)
Completely active; able to perform all their activities without restriction. (Karnofsky
90&#x02013;100%); 1) Restriction of rigorous physical activities, but able to perform light work and
of a sedentary nature (Karnofsky 70&#x02013;80%); 2) Able to perform all self-care, but unable to
carry out any work activity but able to remain standing approximately 50% of waking hours
(Karnofsky 60&#x02013;50%); 3) Capable of only limited self-care, confined to bed or chair more than
50% of waking hours Karnofsky 30&#x02013;40%); 4) Completely unable to perform self-care, totally
confined to bed (Karnofsky 10&#x02013;20%)<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>.</p><p>-Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) for the evaluation of symptoms of
pain and dysesthesia and paresthesia of upper and lower limbs. CINQ is an instrument
containing 20 items to evaluate the symptoms divided into 2 categories: symptoms of acute
and chronic neuropathy in the lower extremities (10 items) and symptoms of acute and chronic
neuropathy in upper extremities (10 items). This questionnaire evaluates the frequency of
symptoms (CINQa) and the symptoms&#x02019; interference with patients&#x02019; daily activities (CINQb).</p><p>Questionnaires were administered before the treatment (Assessment 1: Ax1) and after 15
(Ax2), 30 (Ax3), and 45 (Ax4) days of treatment.</p><p>The data were presented using measures of central tendency (mean and median) and dispersion
(standard deviation) for quantitative variables and relative percentages for categorical
variables. Pearson&#x02019;s &#x003c7;<sup>2</sup> test was used to verify the association between the
categories of the study and, when necessary, resorted to Fisher&#x02019;s exact test. Comparisons of
the VAS scores between groups were performed using the nonparametric statistical
Mann-Whitney U test and comparison of VAS along with the assessments by Friedman ANOVA. The
Q-Cochran test was used to determine differences in the CINQ responses among the evaluations
(Ax1, Ax2, Ax3 and Ax4). The comparison of the sums of scores of CINQ questions among the
assessments was done using hierarchical linear models adjusted for restricted maximum
likelihood. The statistical tests were performed at a significance level of 0.05. The data
analyses were performed in R program version 3.1.1 for Windows.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>The mean age in PTG was 46.3 &#x000b1; 13.7 and 52.7 &#x000b1; 9 in ATG, without significative differences
between them. Assessing the functional status of the active TENS group patients, we found
that 10 patients were between 0 and 1 ECOG degrees, with no or some functional limitations,
while only 1 had more marked limitations related to the inability to work. In the placebo
TENS group, 8 patients had ECOG 0&#x02013;1 and 5 ECOG 2.</p><p>The sample characteristics are summarized in <xref rid="tbl_001" ref-type="table">Table
1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Patient characteristics</title></caption><table frame="hsides" rules="groups"><col width="27.5362%" span="1"/><col width="12.0773%" span="1"/><col width="12.0773%" span="1"/><col width="12.0773%" span="1"/><col width="12.0773%" span="1"/><col width="12.0773%" span="1"/><col width="12.0773%" span="1"/><thead><tr><th rowspan="3" align="center" colspan="1"/><th colspan="2" align="center" rowspan="1">Placebo TENS (n=13)</th><th colspan="2" align="center" rowspan="1">Active TENS (n=11)</th><th colspan="2" align="center" rowspan="1">Total (n=24)</th></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">27.3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">20.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">72.7</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">79.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Marital status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Single</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Married</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">61.5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">90.9</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">75.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Divorced</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">8.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Widowed</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Race/ethnicity</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">62.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Asiatic</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">12.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Admixture</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.7</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">25.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Elementary or less</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">72.7</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">50.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Middle school</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">29.2</td></tr><tr><td align="left" rowspan="1" colspan="1">High school</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">12.5</td></tr><tr><td align="left" rowspan="1" colspan="1">College or higher</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">8.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Works</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">76.9</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">54.5</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Stopped working</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">69.2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">54.5</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">62.5</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">37.5</td></tr></tbody></table><table-wrap-foot><p>Fisher&#x02019;s Exact test</p></table-wrap-foot></table-wrap>. The experimental groups showed no significant differences with regard to
gender, marital status, race, education, employment status, or reductions in their
occupational activity due to the treatment.</p><p><xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Distribution of characteristics of the type and cancer stage according treatment
groups</title></caption><table frame="hsides" rules="groups"><col width="20.7746%" span="1"/><col width="13.2042%" span="1"/><col width="13.2042%" span="1"/><col width="13.2042%" span="1"/><col width="13.2042%" span="1"/><col width="13.2042%" span="1"/><col width="13.2042%" span="1"/><thead><tr><th rowspan="3" valign="bottom" align="center" colspan="1"/><th colspan="2" align="center" rowspan="1">TENS Placebo (n=13)</th><th colspan="2" align="center" rowspan="1">TENS Ativo (n=11)</th><th colspan="2" align="center" rowspan="1">Total (n=24)</th></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Type of tumor</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Breast</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">69.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">54.2</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1">Colorectal</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">45.8</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">T1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">T2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">T3</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">54.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">T4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">8.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">N0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">37.5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">N1</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">45.8</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">N2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9.0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">N3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">M0</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">62.5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">M1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">38.5</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">29.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">M3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Mx</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">8.3</td></tr></tbody></table><table-wrap-foot><p>&#x003c7;<sup>2</sup> test Pearson, *p&#x0003e;0.01</p></table-wrap-foot></table-wrap> shows the disease characteristics among groups in relation to cancer type and
disease stage. No significant differences were observed between the groups in terms of these
characteristics (p&#x0003e;0.05).</p><p>The data relating to the type of chemotherapy performed, different types of therapeutic
treatments undertaken by the patient, and the region in which the patient developed
neuropathy are presented in <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Distribution of the type of treatments performed by patients and the body region
affected by CIPN between groups</title></caption><table frame="hsides" rules="groups"><col width="30.4145%" span="1"/><col width="11.5976%" span="1"/><col width="11.5976%" span="1"/><col width="11.5976%" span="1"/><col width="11.5976%" span="1"/><col width="11.5976%" span="1"/><col width="11.5976%" span="1"/><thead><tr><th rowspan="3" valign="bottom" align="center" colspan="1"/><th colspan="2" align="center" rowspan="1">Placebo TENS</th><th colspan="2" align="center" rowspan="1">Active TENS</th><th colspan="2" align="center" rowspan="1">Total</th></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Chemotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Adjuvant</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">76.9</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">70.8</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Neo-adjuvant</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">25.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Paliative</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">75.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">25.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Radiotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">83.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Hormone therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">84.6</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">81.8</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">83.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Immunotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">100.0</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">100.0</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">100.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Acupuncture</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">7.7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">92.3</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">100.0</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">95.8</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Other medications</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">53.8</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">58.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">46.2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">41.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Involvement</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MMSS</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">69.2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">MMII</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">36.4</td><td align="center" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">33.3</td></tr></tbody></table><table-wrap-foot><p>Fisher&#x02019;s Exact test, *p&#x0003e;0.05</p></table-wrap-foot></table-wrap>. No significant differences were observed in the distribution of the
characteristics between the groups in any of the variables described (p&#x0003e;0.05).</p><p><xref rid="tbl_004" ref-type="table">Table 4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Comparison of mean and standard deviation of the frequency of symptoms (CINQa)
and interference of symptoms in patients&#x02019; daily activities (CINQb) during treatment
with TENS in the experimental groups</title></caption><table frame="hsides" rules="groups"><col width="15.3125%" span="1"/><col width="11.875%" span="1"/><col width="23.75%" span="1"/><col width="23.75%" span="1"/><col width="25.3125%" span="1"/><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Placebo TENS </th><th align="center" rowspan="1" colspan="1">Active TENS </th><th align="center" rowspan="1" colspan="1">Time group</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">CINQa</td><td align="center" rowspan="1" colspan="1">Ax 1</td><td align="center" rowspan="1" colspan="1">13.53 (9.29)</td><td align="center" rowspan="1" colspan="1">12.18 (8.28)</td><td align="center" rowspan="1" colspan="1">0.59*</td></tr><tr><td align="center" rowspan="1" colspan="1">Ax 2</td><td align="center" rowspan="1" colspan="1">11.06 (5.02)</td><td align="center" rowspan="1" colspan="1">8.80 (4.87)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Ax 3</td><td align="center" rowspan="1" colspan="1">9.63 (8.46)</td><td align="center" rowspan="1" colspan="1">8.67 (4.33)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Ax 4</td><td align="center" rowspan="1" colspan="1">6.87 (6.40)</td><td align="center" rowspan="1" colspan="1">7.00 (4.31)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="5" colspan="1">CINQb</td><td align="center" rowspan="1" colspan="1">Ax 1</td><td align="center" rowspan="1" colspan="1">9.61 (7.73)</td><td align="center" rowspan="1" colspan="1">11.27 (8.66)</td><td align="center" rowspan="1" colspan="1">0.85*</td></tr><tr><td align="center" rowspan="1" colspan="1">Ax 2</td><td align="center" rowspan="1" colspan="1">8.18 (6.61)</td><td align="center" rowspan="1" colspan="1">7.59 (4.67)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Ax 3</td><td align="center" rowspan="1" colspan="1">8.46 (8.28)</td><td align="center" rowspan="1" colspan="1">6.43 (4.19)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Ax 4</td><td align="center" rowspan="1" colspan="1">5.50 (5.93)</td><td align="center" rowspan="1" colspan="1">7.00 (4.58)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>*p-value related to hierarchical linear mixed effect models. Ax- (Assessment)</p></table-wrap-foot></table-wrap> shows the behavior of CINQ scores over the application of TENS during the 45
treatment days for the placebo and active groups, indicating that there was no difference
between groups during the treatment performed in any assessment carried out, both in terms
of the frequency of symptoms (p=0.5906) and daily living activities (0.8565). <xref rid="tbl_005" ref-type="table">Table 5</xref><table-wrap id="tbl_005" orientation="portrait" position="float"><label>Table 5.</label><caption><title>Comparison of VAS of pain and numbness/paresthesia intra- and inter-group during
TENS treatment in experimental groups</title></caption><table frame="hsides" rules="groups"><col width="44.8276%" span="1"/><col width="27.5862%" span="1"/><col width="27.5862%" span="1"/><thead><tr><th rowspan="3" align="center" colspan="1"/><th align="center" rowspan="1" colspan="1">Placebo TENS</th><th align="center" rowspan="1" colspan="1">Active TENS </th></tr><tr><th colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Median (IQR)</th><th align="center" rowspan="1" colspan="1">Median (IQR)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PAIN VAS AX1</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;0.0)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">PAIN VAS AX2</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;0.0)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">PAIN VAS AX3</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;0.0)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">PAIN VAS AX4</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;2.0)</td><td align="center" rowspan="1" colspan="1">0.0 (0.0&#x02013;1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td align="center" rowspan="1" colspan="1"><sup>#</sup>0.69</td><td align="center" rowspan="1" colspan="1"><sup>#</sup>0.632</td></tr><tr><td colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">VAS NUMB/PARES Ax1</td><td align="center" rowspan="1" colspan="1">2.0 (2.0&#x02013;6.5)</td><td align="center" rowspan="1" colspan="1">4.0 (1.0&#x02013;7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS NUMB/PARES Ax2</td><td align="center" rowspan="1" colspan="1">5.0 (0.0&#x02013;8.0)</td><td align="center" rowspan="1" colspan="1">1.0 (1.0&#x02013;3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS NUMB/PARES Ax3</td><td align="center" rowspan="1" colspan="1">1.0 (0.0&#x02013;5.0)</td><td align="center" rowspan="1" colspan="1">5.0 (1.0&#x02013;7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS NUMB/PARES Ax4</td><td align="center" rowspan="1" colspan="1">1.5 (0.0&#x02013;3.8)</td><td align="center" rowspan="1" colspan="1">2.0 (1.0&#x02013;2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">p value</td><td align="center" rowspan="1" colspan="1"><sup>#</sup>0.24</td><td align="center" rowspan="1" colspan="1"><sup>#</sup>0.01</td></tr></tbody></table><table-wrap-foot><p>IQR interquartile range (25th. 75th percentile);</p><p><sup>#</sup>p values from Mann-Whitney U test for comparison between assessment</p><p>*p values from Friedman test for comparison between groups</p></table-wrap-foot></table-wrap> shows the comparison of VAS of pain and paresthesia intra- and inter-group
during treatment with TENS in the experimental groups.</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>The results of this study show that the use of TENS with modulating frequencies between
7&#x02005;Hz to 65&#x02005;Hz indicated no significant difference in the symptoms of paresthesia and the
impact of these symptoms on the daily activities among the groups who received applications
of active or placebo TENS. These symptoms, however, do not increase during the three cycles
subsequent to the onset of chemotherapy neuropathy symptoms.</p><p>Painful symptoms were not prevalent in our study. These data corroborate the study of
Wolf<xref rid="r13" ref-type="bibr">13</xref><sup>)</sup> and Pachman<xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>, indicating that numbness and tingling are the most
frequent symptoms of CIPN. The hands were more affected than the feet by the symptoms of
neuropathy, which was corroborated by Zanville&#x02019;s study<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>. Ewetrz&#x02019;s review<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup> states that one of the assumptions for the development of CIPN in
hands and feet relates to the fact that these neurons have long axons and are highly
dependent on transport proteins and other nutrients to work correctly. Taxanes can lead to
disruption of microtubules and mitochondria, leading to a deficit in cell nutrition and
subsequent cell death. Platinum-based drugs can also contribute to cell death by inhibiting
ADN synthesis.</p><p>The effects of TENS on nerve regeneration in rats show a positive effect of low frequency
TENS in this process, presenting density, fiber diameter, and a degree of myelination of
neurons similar to the uninjured rats of the control group<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>. It has been hypothesized that these results relate to the effect of
TENS in the modulation of Ca2 + levels and of injured neurons through voltage-dependent
channels after nerve injury, factors that would contribute to a decrease in the frequency of
the firing of these neurons and stimulate production of neurotrophic factors (BDNF, NGF, and
VEGF) and other transcription factors<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>.
In our study, we use modulating frequencies ranging between 7 and 65&#x02005;Hz. As there are no
studies evaluating the symptoms of paresthesia and the impact of symptoms on daily
activities, we could not compare the results of our study with others to verify if other
TENS frequencies would produce better effects on the outcomes.</p><p>An interesting finding of our study is that there was no significant difference between the
active TENS and TENS placebo groups in the studied variables. It was expected that the
symptoms of paresthesia and pain would get worse during the chemotherapy cycles and this may
not have happened due to the fact that patients expected to receive treatment for neuropathy
symptoms resulting from chemotherapy. This effect was also observed in Rakel&#x02019;s study<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup> for post-surgery pain due to total knee
arthroplasty. Worsening neuropathy symptoms would be expected since the development of
symptoms may occur after the first chemotherapy cycle, worsen after performing subsequent
cycles, and even after the end of treatment<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>.</p><p>Pachman<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r19" ref-type="bibr">19</xref><sup>)</sup> points out that the development of neuropathy after the first
treatment cycle with oxaloplatin is a risk factor for the worsening of these symptoms in
subsequent cycles. Patients treated with paclitaxel also have worsening neuropathy symptoms
over the course of chemotherapy cycles<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup>.
The fact that the patients in this study have not presented worsening symptoms may show a
TENS placebo effect on CIPN. Studies show that TENS placebo operates effectively in
modulating pain<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r21" ref-type="bibr">21</xref><sup>)</sup>. As the current in placebo TENS is applied in the same way as in
active stimulation, but for a period of 30 seconds and then decreasing for the next 15
seconds until reaching zero intensity, the fact that the stimulation performed with placebo
TENS mimics the application of the active TENS may have contributed to this placebo effect.
The application of TENS placebo thus carried out is important since many patients have heard
that TENS produces a feeling of a &#x0201c;small electric shock&#x0201d; and the intensity decreases as the
application time goes on. Some studies, conducting the placebo TENS without
electrostimulation (patient doesn&#x02019;t feel any sensation), show a significant difference
between the group of active TENS and the placebo stimulation group in the studied
parameters, in favor of the active TENS<xref rid="r22" ref-type="bibr">22</xref>, <xref rid="r23" ref-type="bibr">23</xref><sup>)</sup>. Other studies should be performed with
high or low frequency TENS to verify these effects.</p><p>Clinical studies show an efficiency of application of transcutaneous electrical stimulation
on the quality of life of patients with CIPN<xref rid="r24" ref-type="bibr">24</xref>, <xref rid="r25" ref-type="bibr">25</xref><sup>)</sup>; however, these studies were not
placebo-controlled, not allowing for the analysis of the placebo effect on quality of life.
Our study found no improvement in the impact of CIPN in the daily activities of patients
between the active TENS groups and placebo group, suggesting that the placebo effect may
also have contributed to the fact that there was no impairment in the performance of daily
life activities of these patients over the course cycles of chemotherapy.</p><p>Our study has some limitations, such as not accompanying the patients throughout the
chemotherapeutic treatment and not evaluating the effect of TENS on other types of cancer
and neurotoxic drugs.</p><p>The application of TENS with modulating frequencies between 7&#x02005;Hz to 65&#x02005;Hz in patients with
breast and colorectal cancer showed no significant difference in terms of the symptoms of
paresthesia and the impact on daily life activities between the groups that received
application of active TENS and those that received a placebo for chemotherapy treatments
with oxaloplatin and paclitaxol. There was no worsening of symptoms in subsequent cycles of
the onset of CIPN symptoms.</p></sec></body><back><ack><p>We would like to thank FAPESP (S&#x000e3;o Paulo Research Foundation, Process No. 13/13619-9) for
supporting this project.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Costa</surname><given-names>TC</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Anjos</surname><given-names>AC</given-names></name><etal>et al.</etal></person-group>: <article-title>[Chemotherapy-induced peripheral neuropathies: an
integrative review of the literature]</article-title>. <source>Rev Esc Enferm
USP</source>, <year>2015</year>, <volume>49</volume>:
<fpage>335</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="pmid">25992834</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Stubblefield</surname><given-names>MD</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Burton</surname><given-names>AW</given-names></name><etal>et al.</etal></person-group>: <article-title>NCCN task force report: management of neuropathy in
cancer</article-title>. <source>J Natl Compr Canc Netw</source>, <year>2009</year>,
<volume>7</volume>: <fpage>S1</fpage>&#x02013;<lpage>S26</lpage>, quiz S27&#x02013;S28.
</mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Addington</surname><given-names>J</given-names></name><name><surname>Freimer</surname><given-names>M</given-names></name></person-group>: <article-title>Chemotherapy-induced peripheral neuropathy: an update on
the current understanding</article-title>. <source>F1000 Res</source>,
<year>2016</year>, <volume>5</volume>: <fpage>5</fpage>. </mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Hershman</surname><given-names>DL</given-names></name><name><surname>Lacchetti</surname><given-names>C</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name><etal>et al.</etal></person-group>American Society of Clinical Oncology: <article-title>Prevention and
management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:
American Society of Clinical Oncology clinical practice guideline</article-title>.
<source>J Clin Oncol</source>, <year>2014</year>, <volume>32</volume>:
<fpage>1941</fpage>&#x02013;<lpage>1967</lpage>. <pub-id pub-id-type="pmid">24733808</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Chu</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><etal>et al.</etal></person-group>: <article-title>Current use of drugs affecting the central nervous system
for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic
review</article-title>. <source>Support Care Cancer</source>, <year>2015</year>,
<volume>23</volume>: <fpage>513</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="pmid">25256375</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Lu</surname><given-names>MC</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name><name><surname>Hsu</surname><given-names>SF</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of electrical stimulation at different frequencies
on regeneration of transected peripheral nerve</article-title>. <source>Neurorehabil
Neural Repair</source>, <year>2008</year>, <volume>22</volume>:
<fpage>367</fpage>&#x02013;<lpage>373</lpage>. <pub-id pub-id-type="pmid">18663248</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Cavalcante Miranda de Assis</surname><given-names>D</given-names></name><name><surname>Martins Lima</surname><given-names>&#x000ca;</given-names></name><name><surname>Teixeira Goes</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>: <article-title>The parameters of transcutaneous electrical nerve
stimulation are critical to its regenerative effects when applied just after a sciatic
crush lesion in mice</article-title>. <source>BioMed Res Int</source>,
<year>2014</year>, <volume>2014</volume>: <fpage>572949</fpage>. <pub-id pub-id-type="pmid">25147807</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>TJ</given-names></name><name><surname>Coyne</surname><given-names>PJ</given-names></name><name><surname>Parker</surname><given-names>GL</given-names></name><etal>et al.</etal></person-group>: <article-title>Pilot trial of a patient-specific cutaneous
electrostimulation device (MC5-A Calmare<sup>&#x000ae;</sup>) for chemotherapy-induced
peripheral neuropathy</article-title>. <source>J Pain Symptom Manage</source>,
<year>2010</year>, <volume>40</volume>: <fpage>883</fpage>&#x02013;<lpage>891</lpage>.
<pub-id pub-id-type="pmid">20813492</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Silva</surname><given-names>JG</given-names></name><name><surname>Santana</surname><given-names>CG</given-names></name><name><surname>Inoc&#x000ea;ncio</surname><given-names>KR</given-names></name><etal>et al.</etal></person-group>: <article-title>Electrocortical analysis of patients with
intercostobrachial pain treated with TENS after breast cancer surgery</article-title>.
<source>J Phys Ther Sci</source>, <year>2014</year>, <volume>26</volume>:
<fpage>349</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="pmid">24707082</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Sluka</surname><given-names>KA</given-names></name><name><surname>Bjordal</surname><given-names>JM</given-names></name><name><surname>Marchand</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>What makes transcutaneous electrical nerve stimulation
work? Making sense of the mixed results in the clinical literature</article-title>.
<source>Phys Ther</source>, <year>2013</year>, <volume>93</volume>:
<fpage>1397</fpage>&#x02013;<lpage>1402</lpage>. <pub-id pub-id-type="pmid">23641031</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Rakel</surname><given-names>BA</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name><name><surname>Geasland</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>: <article-title>Transcutaneous electrical nerve stimulation for the
control of pain during rehabilitation after total knee arthroplasty: a randomized,
blinded, placebo-controlled trial</article-title>. <source>Pain</source>,
<year>2014</year>, <volume>155</volume>: <fpage>2599</fpage>&#x02013;<lpage>2611</lpage>.
<pub-id pub-id-type="pmid">25270585</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="eref">Instituto Nacional de C&#x000e2;ncer &#x02013;I
NCA: <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/inca/acoes._cap6.pdf">http://bvsms.saude.gov.br/bvs/publicacoes/inca/acoes._cap6.pdf</ext-link> 9 (Accessed
May 13, <year>2014</year>)</mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Wolf</surname><given-names>SL</given-names></name><name><surname>Barton</surname><given-names>DL</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>The relationship between numbness, tingling, and
shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN)
as measured by the EORTC QLQ-CIPN20 instrument, N06CA</article-title>. <source>Support
Care Cancer</source>, <year>2012</year>, <volume>20</volume>:
<fpage>625</fpage>&#x02013;<lpage>632</lpage>. <pub-id pub-id-type="pmid">21479990</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Pachman</surname><given-names>DR</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Seisler</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>: <article-title>Comparison of oxaliplatin and paclitaxel-induced
neuropathy (Alliance A151505)</article-title>. <source>Support Care Cancer</source>,
<year>2016</year>, (<issue>Aug</issue>): <fpage>18</fpage>.</mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Zanville</surname><given-names>NR</given-names></name><name><surname>Nudelman</surname><given-names>KN</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names></name><etal>et al.</etal></person-group>: <article-title>Evaluating the impact of chemotherapy-induced peripheral
neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors
during the first year post-treatment</article-title>. <source>Support Care
Cancer</source>, <year>2016</year>, <volume>24</volume>:
<fpage>4779</fpage>&#x02013;<lpage>4789</lpage>. <pub-id pub-id-type="pmid">27470258</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Ewertz</surname><given-names>M</given-names></name><name><surname>Qvortrup</surname><given-names>C</given-names></name><name><surname>Eckhoff</surname><given-names>L</given-names></name></person-group>: <article-title>Chemotherapy-induced peripheral neuropathy in patients
treated with taxanes and platinum derivatives</article-title>. <source>Acta
Oncol</source>, <year>2015</year>, <volume>54</volume>:
<fpage>587</fpage>&#x02013;<lpage>591</lpage>. <pub-id pub-id-type="pmid">25751757</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>T</given-names></name></person-group>: <article-title>Electrical stimulation to enhance axon regeneration after
peripheral nerve injuries in animal models and humans</article-title>.
<source>Neurotherapeutics</source>, <year>2016</year>, <volume>13</volume>:
<fpage>295</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="pmid">26754579</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Sim&#x000e3;o</surname><given-names>DA</given-names></name><name><surname>Murad</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>: <article-title>Chemotherapy-induced peripheral neuropathy: review for
clinical practice</article-title>. <source>Rev Dor,</source><year>2015</year>,
<volume>6</volume>: <fpage>215</fpage>&#x02013;<lpage>220</lpage>.</mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Pachman</surname><given-names>DR</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Seisler</surname><given-names>DK</given-names></name><etal>et al.</etal></person-group>: <article-title>Clinical course of oxaliplatin-induced neuropathy: results
from the randomized phase III Trial N08CB (Alliance)</article-title>. <source>J Clin
Oncol</source>, <year>2015</year>, <volume>33</volume>:
<fpage>3416</fpage>&#x02013;<lpage>3422</lpage>. <pub-id pub-id-type="pmid">26282635</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Development of peripheral neuropathy and its association
with survival during treatment with nab-paclitaxel plus gemcitabine for patients with
metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III
trial (MPACT)</article-title>. <source>Eur J Cancer</source>, <year>2016</year>,
<volume>52</volume>: <fpage>85</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="pmid">26655559</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Vance</surname><given-names>CG</given-names></name><name><surname>Rakel</surname><given-names>BA</given-names></name><name><surname>Blodgett</surname><given-names>NP</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of transcutaneous electrical nerve stimulation on
pain, pain sensitivity, and function in people with knee osteoarthritis: a randomized
controlled trial</article-title>. <source>Phys Ther</source>, <year>2012</year>,
<volume>92</volume>: <fpage>898</fpage>&#x02013;<lpage>910</lpage>. <pub-id pub-id-type="pmid">22466027</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Eidy</surname><given-names>M</given-names></name><name><surname>Fazel</surname><given-names>MR</given-names></name><name><surname>Janzamini</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Preemptive analgesic effects of Transcutaneous Electrical
Nerve Stimulation (TENS) on postoperative pain: a randomized, double-blind,
placebo-controlled trial</article-title>. <source>Iran Red Crescent Med J</source>,
<year>2016</year>, <volume>18</volume>: <fpage>e35050</fpage>. <pub-id pub-id-type="pmid">27275401</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>&#x000d6;nc&#x000fc;</surname><given-names>E</given-names></name><name><surname>Zincir</surname><given-names>H</given-names></name></person-group>: <article-title>The effect of transcutaneous electrical nerve stimulation
in patients with acute exacerbation of chronic obstructive pulmonary disease: randomized
controlled trial</article-title>. <source>J Clin Nurs</source>,
<year>2016</year>.</mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Coyne</surname><given-names>PJ</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Dodson</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>: <article-title>A trial of Scrambler therapy in the treatment of cancer
pain syndromes and chronic chemotherapy-induced peripheral neuropathy</article-title>.
<source>J Pain Palliat Care Pharmacother</source>, <year>2013</year>,
<volume>27</volume>: <fpage>359</fpage>&#x02013;<lpage>364</lpage>. <pub-id pub-id-type="pmid">24143893</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Pachman</surname><given-names>DR</given-names></name><name><surname>Weisbrod</surname><given-names>BL</given-names></name><name><surname>Seisler</surname><given-names>DK</given-names></name><etal>et al.</etal></person-group>: <article-title>Pilot evaluation of Scrambler therapy for the treatment of
chemotherapy-induced peripheral neuropathy</article-title>. <source>Support Care
Cancer</source>, <year>2015</year>, <volume>23</volume>:
<fpage>943</fpage>&#x02013;<lpage>951</lpage>. <pub-id pub-id-type="pmid">25245776</pub-id></mixed-citation></ref></ref-list></back></article>